You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

LDK378,

Showing 1 - 25 of 28
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma, Cancer Trial in Philadelphia (procedure, genetic, other, behavioral, drug)

Terminated
  • Neuroblastoma
  • Cancer
  • Biopsy
  • +12 more
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Jan 31, 2023

ALK Positive Tumors Trial (ceritinib)

No longer available
  • ALK Positive Tumors
  • (no location specified)
Nov 30, 2021

Non-Small-Cell Lung Cancer Trial in Japan (LDK378)

Completed
Has Results
  • Non-Small-Cell Lung Cancer
  • Nagoya, Aichi, Japan
  • +8 more
Mar 26, 2021

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) Trial in Sunto-gun, Koto, Fukuoka (LDK378)

Completed
  • Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
  • Sunto-gun, Shizuoka, Japan
  • +2 more
Dec 16, 2020

Normal Hepatic Function, Impaired Hepatic Function Trial in United States (LDK378)

Completed
  • Normal Hepatic Function
  • Impaired Hepatic Function
  • Lakewood, Colorado
  • +4 more
Dec 16, 2020

Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma Trial in Guangzhou (BYL719, INC280, LDK378)

Completed
Has Results
  • Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
  • Guangzhou, Guangdong, China
    Novartis Investigative Site
Nov 20, 2020

Glioblastoma, Brain Metastases Trial in Phoenix (ceritinib 750mg)

Completed
  • Glioblastoma
  • Brain Metastases
  • ceritinib 750mg
  • Phoenix, Arizona
    Barrow Brain and Spine
Dec 10, 2020

Anaplastic Lymphoma Kinase (ALK), NSCLC Trial in Worldwide (LDK378, AUY922)

Completed
  • Anaplastic Lymphoma Kinase (ALK)
  • Non-small Cell Lung Cancer
  • Aurora, Colorado
  • +7 more
Dec 16, 2020

Tumors With Aberrations in ALK or ROS1 Trial in United States (Ceritinib)

Terminated
Has Results
  • Tumors With Aberrations in ALK or ROS1
  • Santa Rosa, California
  • +20 more
Mar 12, 2021

NSCLC Trial in Worldwide (Ceritinib, Pemetrexed, Cisplatin)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Woolloongabba, Queensland, Australia
  • +131 more
Oct 24, 2022

NSCLC Trial in Worldwide (Ceritinib, pemetrexed, docetaxel)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Fayetteville, Arkansas
  • +96 more
Dec 19, 2022

ALK-activated Tumors Trial in Worldwide (Ceritinib)

Completed
Has Results
  • ALK-activated Tumors
  • Boston, Massachusetts
  • +22 more
May 27, 2020

NSCLC (NSCLC) Trial in Worldwide (LDK378)

No longer available
  • Non-small Cell Lung Cancer (NSCLC)
  • Chandler, Arizona
  • +50 more
Nov 1, 2020

NSCLC Trial in Worldwide (Ribociclib, Ceritinib)

Completed
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
  • +7 more
Dec 16, 2020

ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,

Terminated
Has Results
  • ALK Fusion Protein Expression
  • +14 more
  • San Francisco, California
    University of California, San Francisco
Jan 14, 2020

Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma

Withdrawn
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Brentuximab Vedotin
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 8, 2019

NSCLC Trial in Worldwide (ceritinib)

Completed
  • Non-Small Cell Lung Cancer
  • Fayetteville, Arkansas
  • +72 more
Feb 7, 2022

Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor Trial in Worldwide (Ceritinib

Terminated
Has Results
  • Tumors With Aberrations in ALK
  • +3 more
  • Ceritinib (LDK378)
  • Brno, Czech Republic, Czechia
  • +13 more
Dec 17, 2019

NSCLC Harboring ROS1 Rearrangement Trial in Seoul (LDK378(Ceritinib))

Unknown status
  • Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
  • Seoul, Korea, Republic of
    Division of Medical Oncology, Yonsei Cancer Center, Yonsei Unive
Jan 9, 2019

NSCLC (NSCLC) Trial in Seoul (LDK378)

Unknown status
  • Non-small Cell Lung Cancer (NSCLC)
  • Seoul, Korea, Republic of
    Yonsei Cancer Center at Yonsei University Medical Center
Jan 9, 2019

NSCLC Trial in China (LDK378)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Beijing, Beijing, China
  • +14 more
Jan 30, 2019

Tumors Characterized by Genetic Abnormalities of ALK Trial in Worldwide (LDK378)

Completed
Has Results
  • Tumors Characterized by Genetic Abnormalities of ALK
  • Aurora, Colorado
  • +20 more
Nov 28, 2018

NSCLC Trial in Worldwide (LDK378)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • Boston, Massachusetts
  • +50 more
Mar 12, 2019

ALK-positive NSCLC Trial in Worldwide (Ceritinib)

Completed
Has Results
  • ALK-positive Non-small Cell Lung Cancer
  • Los Angeles, California
  • +56 more
Apr 8, 2020

Cancer Target Therapy Efficacy

Active, not recruiting
  • Cancer
  • RNA sequencing
  • +5 more
  • Walnut, California
  • +6 more
Sep 13, 2021